Health Center

Ads & Resources

Comprehensive Health Directory

Manage Patient Records

Cancer Videos « Go Back

'Cancer Research' Has Published a Paper on the Activity of MM-121, an ErbB3 Inhibitor, in Ligand-dependent Tumors

Posted By: Anonymous | Posted On: Mar 15,2010 18:30 pm | View: 15 Dana-Farber Cancer Institute, Massachusetts General Hospital Cancer Center, Dana-Farber/Harvard Cancer Center, Cell Signaling Technology, Harvard Medical School and Merrimack Pharmaceuticals collaborated on the MM-121 research. Researchers looked at MM-121 in combination with Erbitux to study efficacy in preclinical cancer models resistant to other targeted therapies. Read More: http://www.prweb.com/releases/2010/03/prweb3733734.htm

Other Health Sources

About Us | Contact Us | Asthma | Cancer | Cardiology | Diabetes | Neurology | Diet & Nutrition | Pediatrics | OB/GYN | General

Copyright © 2008-2012, DoctorsOutlook.com, All Rights Reserved.

Disclaimer: Issuers of the submissions/postings are solely responsible for the content of their submissions. Doctorsoutlook.com can't be held liable for the contents of these submissions. In case any submission damages your benefits or violate your rights in any way, please contact us and we'll remove it immediately.